Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and drug label updates.

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

According to the FDA, Apple’s Sleep Apnea Notification Feature is not intended to diagnose, treat, or aid in the management of sleep apnea.

Simplified screening criteria were developed and found to identify more high-benefit people for lung cancer screening, especially among some minority groups. Simple alternative criteria identified ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Dupilumab significantly reduced severe asthma exacerbations and SCS prescriptions vs omalizumab in patients using add-on maintenance therapy.

Chronic airflow limitation and impaired DLCO were associated with common respiratory symptoms in a middle-aged population.

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

Use of ultra-short-acting β-blockers (esmolol or landiolol) for persistent tachycardia in patients with sepsis may not reduce mortality.

A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.

Gefapixant decreased cough-induced stress urinary incontinence (CSUI) episodes in women with refractory/unexplained chronic cough and CSUI.